ЙОХАНСЕН Туе (DK),МЕРСЕБАК Хенриетта (DK),АКСЕЛЬСЕН Мадс (DK),ЛАНГЕ Мартин (DK)
申请号：
RU2014147674
公开号：
RU2014147674A
申请日:
2013.05.01
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A combination comprising at least a first and a second connection insulin-insulin-like compound for treating a pathological condition or disease in a subject in need thereof, wherein this patient would be useful is the administration of insulin wherein the combination is administered in an amount effective to achieve the desired glycemic control in said individual HbAu defined levels of a subject after administering a combination of at the most abundant meal per day to said subject where the desired glycemic control as a result of this combination is advantageous over any glycemic control achievable equivalent dose IGlar in the subject determined levels HbAu subject after administration to the subject IGlar, and / or wherein the useful glycemic control as a result of this combination includes reduction levels HbAu subject to about 7 or less, after administration of the combination at the most abundant meal per day wherein the first insulin-like compound has a longer effect than the second insulin-like compound wherein the combination administered at very abundant meal per day for a given subekta.2. Combination to achieve glycemic control as claimed in claim 1, wherein the first compound is an insulin-like at least a long-acting insulin, preferably extremely long insulin action. Wherein the first insulin-like compound is a derivative of naturally occurring insulin or insulin analogue and wherein the first insulin-like compound has a side chain attached to the amino group of α-N-terminal amino acid1. Комбинация, включающая по меньшей мере первое инсулиноподобное соединение и второе инсулиноподобное соединение для лечения патологического состояния или заболевания у субъекта, нуждающегося в этом, где данному пациенту было бы полезно введение инсулина где комбинацию вводят в количестве, позволяющем достичь полезного гликемического контроля у указанного субъекта, определяемого уровнями HbA1c у данного субъекта после введения комбинации при самом обильном приеме пищи за
